Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Esperion Therapeutics logo

Esperion Therapeutics

Status and phase

Completed
Phase 1

Conditions

Hyperlipidemia

Treatments

Drug: [14C-ETC-1002]

Study type

Interventional

Funder types

Industry

Identifiers

NCT02044627
1002-011

Details and patient eligibility

About

This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of [14C]-ETC-1002

Enrollment

6 patients

Sex

Male

Ages

30 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy Male Volunteers
  • BMI 10-35 kg/m2

Exclusion criteria

  • Hx of CV, renal, hepatic, chronic respiratory or GI disease
  • Hx of drug or alcohol abuse
  • smoking within 12 mos of screening

Trial design

6 participants in 1 patient group

1 dose of [14C-ETC-1002]
Experimental group
Treatment:
Drug: [14C-ETC-1002]

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems